Search results for: psoriasis

Changing Treatment Patterns for Patients with JIA

Lara C. Pullen, PhD | October 18, 2022

A study from Glerup et al. demonstrated that many patients with juvenile idiopathic arthritis achieved drug-free remission over 18 years of follow-up and that remission rates remained stable between years 8 and 18 of the study period.

Image Case Report: Milk of Urate Bulla

Samantha C. Shapiro, MD | October 10, 2022

A 60-year-old Black woman with a history of stage 3 chronic kidney disease, type 2 diabetes and hypertension presented with a 12-month history of asymmetric polyarthritis of the wrists, metacarpophalangeal (MCP), proximal interphalangeal (PIP), metatarsophalangeal (MTP) and knee joints. The review of systems was unremarkable. She denied oral ulcers, rashes, alopecia, or a history of…

A Case of Nodular Rash & Painful Joints

Vania Lin, MD, MPH, Rebecca Johnson, MD, & Lisa Suter, MD | October 10, 2022

Polyarteritis nodosa (PAN) is a necrotizing vasculitis, predominantly involving medium-sized arteries, that causes systemic disease, and, less commonly, cutaneous-limited disease. The population prevalence for PAN ranges from 2 to 33 per million.1-3 Estimates vary due to the increased recognition and classification of other forms of vasculitides over time and variation in the regional prevalence of…

An Evidence-Based Drug Update & Guidance for Rheumatologists

Samantha C. Shapiro, MD | August 14, 2022

ORLANDO—Despite the COVID-19 pandemic, the past two years have been exciting for rheumatology providers and patients. We’ve seen the U.S. Food & Drug Administration (FDA) approve new therapies and expand indications for established drugs. At the 2022 ACR Education Exchange, Jeffrey Curtis, MD, MS, MPH, Marguerite Jones Harbert-Gene Ball Endowed professor of medicine, Division of…

Updates on PsA: Insights into the Latest Psoriatic Arthritis Treatments & Research

Jason Liebowitz, MD, FACR | August 11, 2022

Ana-Maria Orbai, MD, MHS, addressed the latest research into psoriatic arthritis (PsA), including a comprehensive overview of the latest FDA-approved treatments and their implications for clinical practice.

Phase 2 Study Shows Promising Results for Deucravacitinib in PsA

Michele B. Kaufman, PharmD, BCGP | July 19, 2022

Research has demonstrated that deucravacitinib is significantly more efficacious than placebo for achieving minimal disease activity in patients with active PsA after 16 weeks of treatment.

Spine School: Axial Manifestations of Psoriatic Arthritis

Jason Liebowitz, MD, FACR | July 15, 2022

This EULAR 2022 session emphasized the importance of recognizing the axial manifestations of psoriatic arthritis and treating these symptoms accordingly.

Clinical Guidance & Recommendation Updates for Vasculitis, axSpA & More

Jason Liebowitz, MD, FACR | July 15, 2022

In this EULAR 2022 session, new & revised treatment recommendations for ANCA-associated vasculitis, axial spondyloarthritis & rheumatoid arthritis were presented.

Case Report: Abscess as a Manifestation of Autoinflammatory Disease

Katherine Chakrabarti, MD, & Andrew Vreede, MD | June 14, 2022

Abscesses are typically caused by infections, but some are, instead, sterile. Aseptic abscesses (AAs) are characterized by the same neutrophil-rich histopathology as infectious abscesses; however, they don’t improve with antibiotics. Rather, AAs require treatment with anti-inflammatory medications. Although relatively rare, this phenomenon is important for rheumatologists to recognize given its frequent association with underlying systemic…

European Medicines Agency Committee Issues Positive Opinion for Secukinumab in Pediatric Arthritic Disease

Michele B. Kaufman, PharmD, BCGP | June 2, 2022

In the E.U., secukinumab is edging closer to approval for use in pediatric patients with juvenile idiopathic arthritis (JIA), specifically those with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA). In May, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on expanding its indications.